Received 08/22/2022 review began 08/25/2022 review ended 09/11/2022 published 09/21/2022

HIGHLIGHTS

• who: Heart Failure et al. from the (UNIVERSITY) have published the paper: Received 08/22/2022 Review began 08/25/2022 Review ended 09/11/2022 Published 09/21/2022, in the Journal: (JOURNAL) of September/21,/2022
• what: The following goals are being pursued with this review: Current status of SGLT2i dapagliflozin in congestive heart failure. The aim will be the duration until the first heart failure episode or cardiovascular mortality, which will be analyzed in two independent analyses, encompassing the overall population and those with LVEF of less than 60%. The study will . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.